Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 668-672, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-922239
ABSTRACT
Immune checkpoint inhibitors (ICIs) is a negative regulatory factor antibody, which activates T cells to play an anti-tumor effect in immunotherapy, and can also cause immune-related adverse responses, thereby inducing a series of immune related adverse events (irAEs). Among these irAEs, although the incidence of ICIs-related myocarditis is very low, the fatality rate is significantly higher than other adverse reactions, close to 50%. Clinicians should be vigilant when applying ICIs, but the pathogenesis of ICIs-related myocarditis is still unclear. This article combines the recent research results of ICIs to summarize the mechanism and clinical manifestations of ICIs-related myocarditis, so as to improve clinicians' understanding of the adverse reactions.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Investigación Biomédica
/
Cardiotoxicidad
/
Inhibidores de Puntos de Control Inmunológico
/
Inmunoterapia
/
Miocarditis
/
Neoplasias
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS